Effects of pioglitazone or metformin on bone markers and bone mineral density as well as parameters of atherosclerosis in patients with type 2 diabetes

Effects of pioglitazone or metformin on bone markers and bone mineral density as well as parameters of atherosclerosis in patients with type 2 diabetes - Effects of pioglitazone or metformin on bone metabolism and atherosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001997

Enrollment

Registered

2009-05-22

Start date

2006-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Pioglitazone Metformin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Type 2 diabetes

Exclusion criteria

Exclusion criteria: Nobody had hepatic or renal dysfunction or nutritional derangements. Patients treated with TZDs and metformin were excluded from this study. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study.

Design outcomes

Primary

Measure	Time frame
bone turnover marker, bone mineral density, intima-media thickness, pulse wave velocity	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026